(124)I-L19-SIP for immuno-PET imaging of tumour vasculature and guidance of (131)I-L19-SIP radioimmunotherapy. - Wikidata - awgldk - TriplyDB

(124)I-L19-SIP for immuno-PET imaging of tumour vasculature and guidance of (131)I-L19-SIP radioimmunotherapy.

(124)I-L19-SIP for immuno-PET imaging of tumour vasculature and guidance of (131)I-L19-SIP radioimmunotherapy.

http://www.wikidata.org/entity/Q37258167

about

Theranostic Probes for Targeting Tumor Microenvironment: An Overview.Preclinical molecular imaging of tumor angiogenesis.Phage display and molecular imaging: expanding fields of vision in living subjects.New radiotracers for imaging of vascular targets in angiogenesis-related diseases.Antibody phage display libraries: contributions to oncology.Development, optimization, and validation of novel anti-TEM1/CD248 affinity agent for optical imaging in cancer A comparative immunofluorescence analysis of three clinical-stage antibodies in head and neck cancer The ultimate radiochemical nightmare: upon radio-iodination of Botulinum neurotoxin A, the introduced iodine atom itself seems to be fatal for the bioactivity of this macromolecule.Recent trends in antibody-based oncologic imaging Advances in immuno-positron emission tomography: antibodies for molecular imaging in oncology Positron emission tomography tracers for imaging angiogenesis.The antibody-based targeted delivery of TNF in combination with doxorubicin eradicates sarcomas in mice and confers protective immunity.New strategy for monitoring targeted therapy: molecular imaging.Antibody vectors for imaging.PET imaging with radiolabeled antibodies and tyrosine kinase inhibitors: immuno-PET and TKI-PET.Clinical imaging of tumor angiogenesis.Alternative PET tracers in head and neck cancer. A review.Camelid single-domain antibody-fragment engineering for (pre)clinical in vivo molecular imaging applications: adjusting the bullet to its target.Multimodality Imaging in Tumor Angiogenesis: Present Status and Perspectives Positive progress in immunoPET--not just a coincidence.Different patterns of fibronectin and tenascin-C splice variants expression in primary and metastatic melanoma lesions.Targeting Fibronectin for Cancer Imaging and Therapy.Chemical aspects of metal ion chelation in the synthesis and application antibody-based radiotracers.Aligning physics and physiology: Engineering antibodies for radionuclide delivery.Emerging classes of armed antibody therapeutics against cancer Immunocytokines The antibody-mediated targeted delivery of interleukin-10 inhibits endometriosis in a syngeneic mouse model

P2860

Q30354655-26F24DA5-38AF-4BCC-90A0-3A62C38F551B Q30475818-AE8CB13C-A970-4200-AB9A-62D51059E957 Q33849788-580EC34E-B315-4186-9B54-3117C3B58E6E Q34216877-348D4685-D9EC-413A-AC6E-52404E0CC7A5 Q34323991-4FA2DD0F-DDFB-478D-81D4-4DEA26798BDE Q34334475-01BA68F2-891A-4A41-B08E-8259FCB2DA7A Q35027232-5D8EA0AC-2D11-48D5-9132-328CA5ACD95D Q35264634-90D87450-6D70-4DF0-BF6F-44985B071226 Q35643425-7D6C7E80-6EC2-45A0-8848-65BDA349DCAC Q36339722-D1CE5361-7993-4495-9D4B-F9DAD333FD11 Q36777285-F8E3A5F6-0EFE-4DAB-A56D-B1A6A23BEDEE Q37185752-CEF10589-3A1D-49A9-A419-96318D30963E Q37225316-DFCEE397-156A-486E-9F19-1607BEDA0E89 Q37720850-DF5840EE-25AE-4811-9882-C8862B92F4D7 Q37978157-719568E3-176B-4961-BF13-649F40E6F55B Q38059503-211F0167-10FF-45F6-B91C-E09682618B9D Q38069937-831FFBF4-EA80-4072-815E-365B92878EA8 Q38106992-DD4423B1-DE37-40C7-BAB2-BFF155936CB8 Q41661199-1A6E184B-EF2E-46DF-A76D-2A2F0CB1CCA0 Q42429164-722D5DE6-6DDA-42BA-8297-63915D39A228 Q42489583-4723748D-F9A8-4FB5-BE0E-F583942B677C Q47226151-DF7DCF32-4880-425F-8D03-57968110A87C Q48136353-0680F309-D771-4807-A392-A0851F90F34D Q51740406-BF526A9B-61B6-49D7-B40A-53540901E223 Q57911948-DFA87869-1C37-4395-B26F-352DC11EA78E Q57911975-63B8FC9A-9C41-4B40-B5C7-823B685B4528 Q57912004-9C21457B-F5F8-46E7-AE1D-B38DC6748ED6

P2860

(124)I-L19-SIP for immuno-PET imaging of tumour vasculature and guidance of (131)I-L19-SIP radioimmunotherapy.

http://www.wikidata.org/entity/Q37258167

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 04 March 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

(124)I-L19-SIP for immuno-PET ...... )I-L19-SIP radioimmunotherapy.

@en

type

label

(124)I-L19-SIP for immuno-PET ...... )I-L19-SIP radioimmunotherapy.

@en

prefLabel

(124)I-L19-SIP for immuno-PET ...... )I-L19-SIP radioimmunotherapy.

@en

P1433

Q37258167-AC03FA77-124E-4791-A0CF-A0588FF86B26

P1476

Q37258167-DB860B64-958C-4BB9-9066-74F735A56BFD

P2093

Q37258167-5FF28A2B-2B63-4C5A-B437-4CB022A67455

Q37258167-65A77A13-0588-4E5F-B606-1ED684433572

Q37258167-A317A6F3-9277-4829-B138-1FF73FEA4713

Q37258167-B3B728A3-E71E-4E4A-A8A6-C36E4AE61FEA

Q37258167-B4DB3501-1714-4511-A315-DBBB9917AFEA

Q37258167-D92AC273-CC4A-43F8-8188-C7D93E455288

Q37258167-E701E3B9-4E3D-4068-8E57-6718D32F75E9

Q37258167-FCD9169B-992D-4B5F-9D5C-605305E900DD

Q37258167-FD7A4C64-9F38-492E-BF92-98608DD32D66

P2860

Q37258167-0326D535-6A07-45C2-9181-108BE331C0D3

Q37258167-0506BDCA-DFBE-453B-AB6F-BCCC4177B2C3

Q37258167-0AA62143-7DE0-4536-A960-FA28E801D683

Q37258167-123F5ABB-6819-4933-AC11-89AB1BD2F5E1

Q37258167-135DCE8E-AB80-4604-B583-F517BB840D3F

Q37258167-14CEE62D-E01E-42F9-9AA6-89D893267AE3

Q37258167-150F61E7-5C02-4BA9-80CC-7CDAFA970CE6

Q37258167-273CCBC3-9AC7-43AA-91FB-00A6D5FD3A11

Q37258167-3BA98A8E-7263-4D75-8F46-D9C3CA92F6A5

Q37258167-49EAAE65-2D80-4995-BCA5-36AAC45B26E7

P2888

Q37258167-00A33960-5F50-4E17-A250-F0E4AF7014C2

P304

Q37258167-7086EAAC-5E92-49C4-AB9D-1ECB03F49E19

P31

Q37258167-6727DE11-C8D8-4E39-BF65-B49B93C172BF

P356

Q37258167-51ED67D1-280D-4963-89BF-7A573DE617A6

P433

Q37258167-1AAFD0D2-801A-43DC-802E-18BF9951BC4D

P478

Q37258167-A911E870-ED06-4E98-899F-F7C1F89F7A29

P50

Q37258167-25BC7545-271C-42CA-967D-E64C668BC544

P577

Q37258167-BF94A491-4B32-4B38-BEEF-0BC75AEFD12C

P5875

Q37258167-3F013B81-C0F2-4368-B9BA-6E7832781B4A

P698

Q37258167-F0B37138-CC7E-43FE-AFD1-8D70B0B8379A

P932

Q37258167-74C160E6-49B4-47E8-8792-C81F6BABA43B

P356

S00259-009-1096-Y

P1433

European Journal of Nuclear Medicine and Molecular Imaging

P1476

(124)I-L19-SIP for immuno-PET ...... )I-L19-SIP radioimmunotherapy.

@en

P2093

Bernard M Tijink

http://www.w3.org/2001/XMLSchema#string

C René Leemans

http://www.w3.org/2001/XMLSchema#string

Gerard W M Visser

http://www.w3.org/2001/XMLSchema#string

Guus A M S van Dongen

http://www.w3.org/2001/XMLSchema#string

Lars R Perk

http://www.w3.org/2001/XMLSchema#string

Ludger M Dinkelborg

http://www.w3.org/2001/XMLSchema#string

Marianne Budde

http://www.w3.org/2001/XMLSchema#string

Marijke Stigter-van Walsum

http://www.w3.org/2001/XMLSchema#string

Reina W Kloet

http://www.w3.org/2001/XMLSchema#string

P2860

Design and use of a phage display library. Human antibodies with subnanomolar affinity against a marker of angiogenesis eluted from a two-dimensional gel.

Development of radioimmunotherapeutic and diagnostic antibodies: an inside-out view.

Diagnostic and therapeutic applications of recombinant antibodies: targeting the extra-domain B of fibronectin, a marker of tumor angiogenesis.

The promise of immuno-PET in radioimmunotherapy.

Tumour vascular targeting.

A tumor-associated fibronectin isoform generated by alternative splicing of messenger RNA precursors

Characterisation and radioimmunotherapy of L19-SIP, an anti-angiogenic antibody against the extra domain B of fibronectin, in colorectal tumour models.

Ligand-based vascular targeting of disease.

Antibody-based targeting of the tumor vasculature.

Immuno-PET: a navigator in monoclonal antibody development and applications.

P2888

s00259-009-1096-y

P304

1235-1244

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00259-009-1096-Y

http://www.w3.org/2001/XMLSchema#string

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

36

http://www.w3.org/2001/XMLSchema#string

P50

P577

2009-03-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

245602525

http://www.w3.org/2001/XMLSchema#string

P698

19259661

http://www.w3.org/2001/XMLSchema#string

P932

2709218

http://www.w3.org/2001/XMLSchema#string